We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00596401
Recruitment Status : Active, not recruiting
First Posted : January 17, 2008
Last Update Posted : October 5, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Recently, the preventive effect of Helicobacter pylori (Hp) eradication treatment on the incidence of gastric cancer has been reported. By Hp eradication treatment being performed for Hp-infected people in Iijima town, we will evaluate whether the incidence of gastric cancer and/or the medical care cost can be reduced as compared with those in the previous years.

Condition or disease
Helicobacter Pylori Eradication Gastric Cancer Medical Care Cost

Study Design

Study Type : Observational
Actual Enrollment : 3000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer and the Medical Care Cost in Iijima Town
Study Start Date : September 2007
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : August 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
1
HP eradication group
2
No eradication group
3
No Hp group


Outcome Measures

Primary Outcome Measures :
  1. the annual incidence of gastric cancer in Iijima town [ Time Frame: 10 years ]

Secondary Outcome Measures :
  1. The annual medical care cost in Iijima town [ Time Frame: 10 years ]

Biospecimen Retention:   Samples Without DNA
serum

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
People who live in Iijima town
Criteria

Inclusion Criteria:

  • People who live in Iijima town at their age of 19 to 69 years
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00596401


Locations
Japan
Showa Inan General hospital
Komagane, Nagano, Japan, 399-4191
Sponsors and Collaborators
Showa Inan General Hospital
Investigators
Study Director: Akira Horiuchi, M.D. Showa Inan General Hospital
More Information

Responsible Party: Akira Horiuchi, Digestive Disease Center, Showa Inan General Hospital
ClinicalTrials.gov Identifier: NCT00596401     History of Changes
Other Study ID Numbers: sihp20076
First Posted: January 17, 2008    Key Record Dates
Last Update Posted: October 5, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases